ACUMEN

ACU193

This clinical trial examines ACU193 for how it affects individuals with mild Alzheimer’s disease or mild cognitive impairment (MCI). This new antibody binds to the Aβ-derived diffusible ligands (ADDLs), which are believed to increase memory problems and brain cell death.

Eligibility: Individuals with mild Alzheimer’s disease or mild cognitive impairment (MCI).

Status: RECRUITING

Study Details

Application











    All information provided is confidential and will not be given or sold to any other agency without prior consent.